TY - JOUR
T1 - Three week compared to seven week run-in period length and the assessment of pre-randomization adherence
T2 - A study within a trial
AU - On behalf of the ACHIEVE investigators
AU - Collister, David
AU - Mbuagbaw, Lawrence
AU - Guyatt, Gordon
AU - Devereaux, P. J.
AU - Tennankore, Karthik K.
AU - Reis, Gilmar
AU - Sola, Laura
AU - Xavier, Denis
AU - Jha, Vivekanand
AU - Gallagher, Martin
AU - Dans, Antonio L.
AU - Liu, Wen
AU - de Zoysa, Janak
AU - Félix, Camilo
AU - Mark, Patrick B.
AU - Li, Zuo
AU - Tyrwhitt, Jessica
AU - Wilkinson, Joanne
AU - Sheridan, Patrick
AU - Yuan, Fei
AU - Walsh, Michael
N1 - Publisher Copyright:
© 2021
PY - 2021/8
Y1 - 2021/8
N2 - Background/aims: To examine how measuring adherence at 3 weeks by self-report and pill counts compares to measurements at 7 weeks in a pre-randomization run-in period. Methods: Study within a trial of an international parallel group randomized controlled trial (RCT) that compares spironolactone to placebo. Adults receiving dialysis enter an 8-week active run-in period with spironolactone. Adherence was assessed by both self-report and pill counts in a subgroup of participants at both 3 weeks and 7 weeks. Results: 332 participants entered the run-in period of which 166 had complete data. By self-report, 146/166 (94.0%) and 153/166 (92.2%) had at least 80% adherence at 3 and 7 weeks respectively (kappa = 0.27 (95% C.I. 0.16 to 0.38). By pill counts, the mean (SD) adherence was 96.5% (16.1%) and 92.4% (18.2%) at 3 and 7 weeks respectively (r = 0.32) with a mean (SD) difference of 3.1% (17.8%) and a 95% limit of agreement from −31.7% to +37.9%. The proportion of adherent participants by self-report and pill counts at 3 weeks agreed in 87.4% of participants (McNemar's p-value 0.58, kappa 0.11, p = 0.02) and at 7 weeks agreed in 92.2% (McNemar's p-value 0.82, kappa 0.47, p < 0.001). Conclusions: Three and seven-week run-in periods and both self-reported and pill count assessments performed similarly. Trial registration: ClinicalTrials.gov Identifier: NCT03020303
AB - Background/aims: To examine how measuring adherence at 3 weeks by self-report and pill counts compares to measurements at 7 weeks in a pre-randomization run-in period. Methods: Study within a trial of an international parallel group randomized controlled trial (RCT) that compares spironolactone to placebo. Adults receiving dialysis enter an 8-week active run-in period with spironolactone. Adherence was assessed by both self-report and pill counts in a subgroup of participants at both 3 weeks and 7 weeks. Results: 332 participants entered the run-in period of which 166 had complete data. By self-report, 146/166 (94.0%) and 153/166 (92.2%) had at least 80% adherence at 3 and 7 weeks respectively (kappa = 0.27 (95% C.I. 0.16 to 0.38). By pill counts, the mean (SD) adherence was 96.5% (16.1%) and 92.4% (18.2%) at 3 and 7 weeks respectively (r = 0.32) with a mean (SD) difference of 3.1% (17.8%) and a 95% limit of agreement from −31.7% to +37.9%. The proportion of adherent participants by self-report and pill counts at 3 weeks agreed in 87.4% of participants (McNemar's p-value 0.58, kappa 0.11, p = 0.02) and at 7 weeks agreed in 92.2% (McNemar's p-value 0.82, kappa 0.47, p < 0.001). Conclusions: Three and seven-week run-in periods and both self-reported and pill count assessments performed similarly. Trial registration: ClinicalTrials.gov Identifier: NCT03020303
UR - http://www.scopus.com/inward/record.url?scp=85107698362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107698362&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2021.106466
DO - 10.1016/j.cct.2021.106466
M3 - Article
C2 - 34098039
AN - SCOPUS:85107698362
SN - 1551-7144
VL - 107
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
M1 - 106466
ER -